High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia

British Journal of Haematology
B CazinKarim Maloum

Abstract

A multicentre single-arm study testing the efficacy and toxicity of the oral combination of fludarabine and cyclophosphamide (FC) over 5 d in 75 patients with untreated B cell-chronic lymphocytic leukaemia. Oral FC demonstrated high efficacy with overall (OR) and complete response (CR) rates of 80% and 53%, respectively. Out of the 30 CR patients studied for Minimal Residual Disease (MRD) using 4-colour flow-cytometry and the 22 using Clonospecific polymerase chain reaction, 22 (66%) and 16 (68%), respectively, were MRD negative. Median survival and median treatment-free interval had not been reached at 7 years of follow-up. Median progression-free survival (PFS) was 5 years. Toxicity was acceptable, with 52% and 16% of National Cancer Institute grade 3/4 neutropenia and infections, respectively. Gastrointestinal toxicity was mild. Oral FC demonstrated a high efficacy and an acceptable safety profile and may be considered as the standard first line treatment in chronic lymphocytic leukaemia.

References

Aug 1, 1990·Statistics in Medicine·E BellissantC Chastang
Apr 8, 1999·Hematology and Cell Therapy·C MagnacK Maloum
Dec 15, 2000·The New England Journal of Medicine·K R RaiC A Schiffer
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S M O'BrienM Keating
Aug 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V A MorrisonC A Schiffer
Oct 6, 2001·Blood·M LeporrierUNKNOWN French Cooperative Group on Chronic Lymphocytic Leukemia
Nov 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A BoogaertsM Klein
Mar 29, 2002·The Hematology Journal : the Official Journal of the European Haematology Association·D OscierH Gieschen
Mar 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J-F RossiS M Tollerfield
Sep 8, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas ElterAndreas Engert
Dec 14, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John C ByrdNyla A Heerema
Apr 19, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marco MontilloEnrica Morra
Jun 6, 2006·The Lancet Oncology·Asher Chanan-Khan, Carl W Porter
Feb 7, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ian W FlinnMartin S Tallman

❮ Previous
Next ❯

Citations

May 18, 2013·Journal of Hematology & Oncology·Mei WuXiongpeng Zhu
May 14, 2009·Therapeutics and Clinical Risk Management·Francesca RicciMarco Montillo
Jan 8, 2010·Drug Design, Development and Therapy·Ann JanssensGregor Verhoef
Sep 3, 2011·Leukemia Research·Francesca Romana MauroUNKNOWN Gruppo Italiano Trapianto di Midollo Osseo
Aug 12, 2006·Mayo Clinic Proceedings·Karen W L Yee, Susan M O'Brien
Feb 15, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sebastian BöttcherMichael Kneba
Sep 13, 2017·Expert Opinion on Biological Therapy·Rabih Said, Apostolia M Tsimberidou

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.